摘要
目的探讨灯盏花素联合单硝酸异山梨酯治疗对急性心肌梗死(AMI)心功能、肌酸激酶同工酶(CK⁃MB)及纤溶酶原激活物抑制物⁃1(PAI⁃1)水平的影响。方法选取2016年6月至2019年9月上海交通大学附属第六人民医院南院住院部收治的227例AMI患者,根据治疗方案不同分为对照组119例(单一单硝酸异山梨酯片治疗)、观察组108例(单硝酸异山梨酯片+灯盏花素分散片治疗)。比较两组临床疗效,比较治疗前后CK⁃MB、PAI⁃1水平及心功能指标[左室舒张末期内径(LVEDD)、每搏量(SV)、左心室射血分数(LVEF)、左房内径(LAD)]改善情况,观察治疗过程中不良反应总发生率。结果观察组患者总有效率显著高于对照组(88.89%vs 77.31%),差异有统计学意义(P<0.05)。治疗后两组CK⁃MB、PAI⁃1水平均明显下降,且观察组下降幅度显著大于对照组,差异有统计学意义(P<0.05)。治疗后两组患者LVEDD、SV、LVEF、LAD水平均得到改善,且观察组上述指标改善幅度均大于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率(7.41%vs 5.88%)比较差异无统计学意义(P>0.05)。结论对AMI患者予以灯盏花素联合单硝酸异山梨酯治疗可提高治疗疗效,改善心功能,降低CK⁃MB、PAI⁃1水平,是一种安全的治疗方案。
Objective To explore the effects of breviscapine combined with isosorbide mononitrate treatment on acute myocardial infarction(AMI)cardiac function,creatine kinase isoenzyme(CK⁃MB)and plasminogen activator inhibitor⁃1(PAI⁃1)levels.Methods The 227 patients with AMI admitted to the Academic Department of the Sixth People's Hospital of Shanghai Jiaotong University from June 2016 to September 2019 were selected,and according to the different treatment plans,they were divided into 119 cases in the control group(single isosorbide mononitrate tablets)and 108 cases in the observation group(isosorbide mononitrate tablets+scutellarin dispersible tablets).The clinical efficacy of the two groups were compared,the levels of CK⁃MB,PAI⁃1,and the improvement of cardiac function indexes[Left ventricular end diastolic diameter(LVEDD),stroke volume(SV),left ventricular ejection fraction(LVEF),left atrial diameter(LAD)]before and after treatment were compared,and the total incidence of adverse reactions during the treatment were observed.Results The total effective rate of patients in the observation group was significantly higher than that in the control group(88.89%vs 77.31%),and the difference was statistically significant(P<0.05).After treatment,the levels of CK⁃MB and PAI⁃1 in the two groups decreased significantly,and the decrease in the observation group was significantly greater than that in the control group,and the difference was statistically significant(P<0.05).Compared with those before treatment,the levels of LVEDD,SV,LVEF,and LAD in the two groups were improved after treatment,the improvement of the above indicators in the observation group was greater than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(7.41%vs 5.88%),and the difference was statistically significant(P>0.05).Conclusion Breviscapine combined with isosorbide mononitrate in the treatment of AMI patients c
作者
邓海燕
陶元
王芳
郑文权
乔增勇
DENG Haiyan;TAO Yuan;WANG Fang;ZHENG Wenquan;QIAO Zengyong(Department of Cardiovascular Medicine,Shanghai Jiao Tong University Affiliated Sixth People's Hospital South Campus,Shanghai,China,201499)
出处
《分子诊断与治疗杂志》
2022年第4期701-704,共4页
Journal of Molecular Diagnostics and Therapy
基金
上海市科学技术委员会(18DZ2260236)。
